Debts and desperation: Australian blood cancer patients at high risk of financial toxicity

Getting into debt, resorting to food banks and skipping treatment are some of the manifestations of financial toxicity experienced by Australian patients with haematological cancers, a study shows. While Australia has a publicly-funded health system, patients with haematological cancer still face...

Getting into debt, resorting to food banks and skipping treatment are some of the manifestations of financial toxicity experienced by...

Blood cancers

Long term impact of COVID-19 is cause for concern in haematological cancer patients

The first study of the long term impact of COVID-19 in cancer patients has revealed that fatigue, respiratory symptoms and worsened oncological outcomes may be issues for many patients. Also of concern is a finding that some COVID-19 survivors, particularly those...

The first study of the long term impact of COVID-19 in cancer patients has revealed that fatigue, respiratory symptoms and...

News in brief: TGA approves belumosudil for GVHD; Alloimmunisation common in Sickle Cell Disease patients; Specialty training colleges’ ‘dirty secret’

TGA approves belumosudil for GVHD Australian graft-versus-host disease patients’ treatment horizon has just expanded with the first-in-class approval of belumosudil (Rholistiq). The oral serine/threonine kinase inhibitor, developed by Kadmon (now owned by Sanofi), is indicated for the “treatment of patients 12 years...

TGA approves belumosudil for GVHD Australian graft-versus-host disease patients’ treatment horizon has just expanded with the first-in-class approval of belumosudil (Rholistiq). The...

Blood cancers

Venetoclax funded as an option for AML patients not eligible for intensive chemo

Venetoclax will be listed on the PBS from 1 December for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML), ineligible for standard intensive remission induction chemotherapy, given in combination with azacytidine. The expended listing is expected to provide...

Venetoclax will be listed on the PBS from 1 December for the treatment of patients with newly diagnosed acute myeloid...